Glucagon-like peptide-1 (GLP-1) and GIP/GLP-1 agents are just the start: amylin- and glucagon-based mono-, dual-, and tri-therapies are on the horizon.
Robert Kushner, MD, MS
Advertisement
Articles by Robert Kushner, MD, MS
Advertisement
Latest Updated Articles
Beyond GLP-1: Amylin, Glucagon Enter Obesity CareSeptember 1st 2026
Reframing Obesity: It's Biology, and It's Not Your FaultSeptember 10th 2026
Advertisement
Advertisement
Trending on Pharmacy Times
1
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
2
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
3
Dostarlimab Receives FDA Accelerated Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
4
Fall 2026 Quiz: Test Your Pharmacy Knowledge!
5